Chemokines in neoplastic progression
Chemokines in neoplastic progression
复制标题
DOI：
10.1016/j.semcancer.2003.10.004
复制
发表时间：
2004-06-01
影响因子：
14.5
通讯作者：
Zlotnik, A
中科院分区：
文献类型：
--
作者：
Zlotnik, A
趋化因子及其受体已成为调节肿瘤细胞在体内迁移的有吸引力的靶点，这一过程被称为癌症转移。控制转移是控制肿瘤进展的关键。两种趋化因子受体及其配体是治疗的可能靶点：CCR7/CCL21用于淋巴结转移，CXCR4/CXCL12用于肺、肝、骨髓和脑转移。在癌症中最广泛表达的趋化因子受体可能是CXCR4。(C) 2003, Elsevier Ltd.出版
Chemokines and their receptors have emerged as attractive targets regulating the migration of tumor cells in vivo, a process known as cancer metastasis. The control of metastasis is critical to the control of cancer progression. Two chemokine receptors and their ligands stand out as likely targets for therapeutics: CCR7/CCL21 for lymph node metastases, and CXCR4/CXCL12 for lung, liver, bone marrow, and brain metastases. The most widely expressed chemokine receptor among cancers is likely to be CXCR4. (C) 2003 Published by Elsevier Ltd.